Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (9075)	9/8/2006 10:27:53 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 10345

44% reduction in Gd-Enhanced active lesions seems like relative poor efficacy compared even to INFb or Glatiramer Acetate. My recollection is that even INFb produces twice that difference - and Tysabri is perhaps two orders of magnitude better than INFb. (For example, after only 6 months 30% of INFb patients had at least one new Gd-Enhanced lesion and at 2 years only 3% of Tysabri patients had at least one new lesion.) Laquinimod seems to be a poor bet to me... but then I would have said the same about Copaxone whose study rho values were 0.055 and 0.08...